Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Table 1 Pre-treatment biopsy PDX by clinical molecular subtype

Clinical molecular subtype	Total implanted^a	Any tumor growth	Verified human breast tumor (%)	pCR
Clinical molecular subtype	Total implanted^a	Any tumor growth	Verified human breast tumor (%)	no	yes
ER-/HER2+	20	6	5 (25.0)	4/8	1/12
ER+/HER2+	14	5	4 (28.6)	3/11	1/3
LumA	9	0	0 (0.0)	0/9	0/0
LumB	30	6	2 (6.7)	0/27	2/3
LumUnk	1	0	0 (0.0)	0/1	0/0
Triple negative	39	21	20 (51.3)	9/17	11/22
Total	113	38	31 (27.4)	16/73	15/40

Abbreviations: PDX patient-derived xenograft, pCR pathological complete response, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, LumA luminal A, LumB luminal B, LumUnk luminal unknown
^aAn additional seven tumors were implanted and had growth but were not available for pathological confirmation n

ISSN: 1465-542X